Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial

Xiao-Jun Zhou, Lin Ding, Jia-Xin Liu, Le-Qun Su, Jian-Jun Dong, Lin Liao, Xiao-Jun Zhou, Lin Ding, Jia-Xin Liu, Le-Qun Su, Jian-Jun Dong, Lin Liao

Abstract

Aims: To investigate the difference in the efficacy among dipeptidyl peptidase-4 (DPP-4) inhibitors in Chinese adults with newly diagnosed diabetes.

Materials and methods: In a multicenter, randomized study, we enrolled adults who were either treatment naive or off prior anti-hyperglycemic therapy for at least 3 months. Eligible patients had hemoglobin A1c (HbA1c) concentrations of 6.5-9.5%. Three hundred patients had been randomly allocated to sitagliptin 100 mg, once daily; vildagliptin 50 mg, twice daily and saxagliptin 5 mg, once daily for 12 weeks. Patients and investigators were masked to treatment assignment. The primary endpoint was change from baseline in HbA1c at week 12. This study was completed and registered with ClinicalTrials.gov, number NCT01703637.

Results: Totally 277 patients were enrolled in the final analysis, and 93 patients received sitagliptin, 94 received vildagliptin and 90 received saxagliptin. Compared with baseline, adjusted mean differences in change from baseline HbA1c at week 12 were -0.50% (95% CI: -0.20 to -0.90), -0.65% (95% CI: -0.40 to -1.40), -0.70 (95% CI: -0.50 to -1.00) for sitagliptin, vildagliptin and saxagliptin group, respectively. The overall HbA1c-lowering effect was similar for all three selected DPP-4 inhibitors after adjustment for age and baseline HbA1c. Notably, in secondary outcome analysis, patients in vildagliptin group showed a significant decrease in total cholesterol levels, compared with participants in sitagliptin and saxagliptin groups. No significant between-group difference was shown in adverse events (AE).

Conclusions: The overall HbA1c-lowering effect and incidence of AE were similar for sitagliptin, vildagliptin and saxagliptin in Chinese adults with newly diagnosed diabetes.

Keywords: Chinese; diabetes; dipeptidyl peptidase-4 inhibitors; hemoglobin A1c.

Figures

Figure 1
Figure 1
Hemoglobin A1c (HbA1c) levels among sitagliptin, vildagliptin and saxagliptin groups from baseline to week 12.

References

    1. International Diabetes Federation. IDF Diabetes Atlas, 8th ed Brussels, Belgium: IDF. (available at: )
    1. Wang L, Gao P, Zhang M, Huang Z, Zhang D, Deng Q, Li Y, Zhao Z, Qin X, Jin D, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA 2017. 317 2515–2523. (10.1001/jama.2017.7596)
    1. Edelman SV, Polonsky WH. Type 2 diabetes in the real world: the elusive nature of glycemic control. Diabetes Care 2017. 40 1425–1432. (10.2337/dc16-1974)
    1. Xu Y, Wang L, He J, Bi Y, Li M, Wang T, Wang L, Jiang Y, Dai M, Lu J, et al. Prevalence and control of diabetes in Chinese adults. JAMA 2013. 310 948–959. (10.1001/jama.2013.168118)
    1. Connelly KA, Yan AT, Leiter LA, Bhatt DL, Verma S. Cardiovascular implications of hypoglycemia in diabetes mellitus. Circulation 2015. 132 2345–2350. (10.1161/CIRCULATIONAHA.115.015946)
    1. American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care 2018. 41 S73–S85. (10.2337/dc18-S008)
    1. Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Management of hyperglycemia in Type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018. 41 2669–2701. (10.2337/dci18-0033)
    1. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2014. 130 1579–1588. (10.1161/CIRCULATIONAHA.114.010389)
    1. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. New England Journal of Medicine 2013. 369 1317–1326. (10.1056/NEJMoa1307684)
    1. Munir KM, Lamos EM. Diabetes type 2 management: what are the differences between DPP-4 inhibitors and how do you choose? Expert Opinion on Pharmacotherapy 2017. 18 839–841. (10.1080/14656566.2017.1323878)
    1. Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 2013. 56 696–708. (10.1007/s00125-012-2827-3)
    1. Sjostrand M, Wei C, Cook W, Johnsson K, Pollack PS, Stahre C, Hirshberg B. Assessment of saxagliptin efficacy: meta-analysis of 14 Phase 2 and 3 clinical trials. Diabetes Therapy 2017. 8 587–599. (10.1007/s13300-017-0261-8)
    1. Bekiari E, Rizava C, Athanasiadou E, Papatheodorou K, Liakos A, Karagiannis T, Mainou M, Rika M, Boura P, Tsapas A. Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. Endocrine 2016. 52 458–480. (10.1007/s12020-015-0841-1)
    1. Zhan M, Xu T, Wu F, Tang Y. Sitagliptin in the treatment of type 2 diabetes: a meta-analysis. Journal of Evidence-Based Medicine 2012. 5 154–165. (10.1111/j.1756-5391.2012.01189.x)
    1. Chu WM, Ho HE, Huang KH, Tsan YT, Liou YS, Wang YH, Lee MC, Li YC. The prescribing trend of oral antidiabetic agents for type 2 diabetes in Taiwan: an 8-year population-based study. Medicine 2017. 96 e8257 (10.1097/MD.0000000000008257)
    1. Hampp C, Borders-Hemphill V, Moeny DG, Wysowski DK. Use of antidiabetic drugs in the U.S., 2003–2012. Diabetes Care 2014. 37 1367–1374. (10.2337/dc13-2289)
    1. The Express Scripts Lab. Drug Trend Report 2016. St Louis, MI, USA: Express Scripts; (available at: )
    1. Farr AM, Sheehan JJ, Curkendall SM, Smith DM, Johnston SS, Kalsekar I. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus. Advances in Therapy 2014. 31 1287–1305. (10.1007/s12325-014-0171-3)
    1. Li CJ, Liu XJ, Bai L, Yu Q, Zhang QM, Yu P, Yu DM. Efficacy and safety of vildagliptin, saxagliptin or sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents. Diabetology and Metabolic Syndrome 2014. 6 69 (10.1186/1758-5996-6-69)
    1. Tatosian DA, Guo Y, Schaeffer AK, Gaibu N, Popa S, Stoch A, Langdon RB, Kauh EA. Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin. Diabetes Therapy 2013. 4 431–442. (10.1007/s13300-013-0045-8)
    1. Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, Ouwens DM, Eckardt K, Kaufman JM, Ryden M, Muller S, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011. 60 1917–1925. (10.2337/db10-1707)
    1. Turcot V, Tchernof A, Deshaies Y, Perusse L, Belisle A, Marceau P, Hould FS, Lebel S, Vohl MC. Comparison of the dipeptidyl peptidase-4 gene methylation levels between severely obese subjects with and without the metabolic syndrome. Diabetology and Metabolic Syndrome 2013. 5 4 (10.1186/1758-5996-5-4)

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe